Genentech, Inc. (DNA) - Financial and Strategic Analysis Review

Document Sample
Genentech, Inc. (DNA) - Financial and Strategic Analysis Review Powered By Docstoc
					               Genentech, Inc. (DNA) - Financial and Strategic Analysis Review

       Reference Code: GDPH4341FSA                                                                                     Publication Date: SEP 2010

       1 DNA Way                             Phone            +1 650 2251000                   Revenue            13,418 (million USD)
       South San Francisco, CA               Fax              +1 650 2256000                   Net Profit         NA
       94080-4990                            Website          www.gene.com                     Employees          11,186
                                             Exchange         DNA [New York Stock              Industry
       United States                                                                                              Pharmaceuticals & Healthcare
                                                              Exchange]

      Company Overview
       Genentech, Inc. (Genentech) is a biotechnology company focused on research and development, manufacture, and marketing of
       biotherapeutics. Genentech is developing the drugs across the unmet medical needs in cancer, asthma and angiogenic
       disorders. Genentech's major focus is on three areas of oncology, immunology, and tissue growth and repair. During March 2009,
       the company has been acquired by Roche Holding Ltd (Roche), following the acquisition Genentech became the wholly owned
       subsidiary of Roche. Its research focus areas include oncology, immunology, neuroscience, infectious disease and disorders of
       tissue growth and repair.

      Key Executives                                                             SWOT Analysis
                     Name                                  Title                 Genentech, Inc., SWOT Analysis
      Arthur D. Levinson, Ph.D.            Chairman                              Strengths                  Weaknesses

      Ian T. Clark                         Chief Marketing Officer
                                                                                 Expanding Operating Margin          Legal Proceedings
      Richard H. Scheller, Ph.D.           Executive Vice President,
                                           Research & Early Development          Strong Liquidity Position           Limited Customer Base
      Patrick Y. Yang, Ph.D                Executive Vice President,
                                           Technical Operations
      Marc Tessier-Lavigne, Ph.D           Chief Scientific Officer              Opportunities                       Threats
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                 Product Pipeline                    Industry Consolidation
      Share Data
       Genentech, Inc.                                                           Changing Demographics               Competition from Generic
                                                                                                                     Cancer Drugs
       Share Price (USD) as on 26-Mar-2009                                95.0

       EPS (USD)                                                          3.21

       Market Cap (million USD)                                       100,043    Source: Annual Report, Company Website, Primary and Secondary Research

       Enterprise Value (million USD)                                  98,339    GlobalData

       Shares Outstanding (million)                                      1,053
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData

      Financial Performance                                                      Recent Developments
                                                                                 Aug 03, 2010        Seattle Genetics Expands Antibody-Drug
                                                                                                     Conjugate
				
DOCUMENT INFO
Description: Genentech, Inc. (Genentech) is a biotechnology company focused on research and development, manufacture, and marketing of biotherapeutics. Genentech is developing the drugs across the unmet medical needs in cancer, asthma and angiogenic disorders. Genentech's major focus is on three areas of oncology, immunology, and tissue growth and repair. During March 2009, the company has been acquired by Roche Holding Ltd (Roche), following the acquisition Genentech became the wholly owned subsidiary of Roche. Its research focus areas include oncology, immunology, neuroscience, infectious disease and disorders of tissue growth and repair. Genentech, Inc. Key Recent Developments Aug 03, 2010 Seattle Genetics Expands Antibody-Drug Conjugate Collaboration With Genentech Apr 23, 2010 Genentech Files Herceptin Supplemental Biologics License Application To FDA Apr 21, 2010 Seattle Genetics To Get Payment From Genentech Under Antibody-Drug Conjugate Collaboration Mar 30, 2010 Studies Using Taconic HRN Mouse Featured At North American Regional ISSX Meeting Mar 26, 2010 Genentech, Biogen Idec File Declaratory Relief Complaint Against GSK This comprehensive SWOT profile of Genentech, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Pr
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.